Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
33 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
D2.115 - Association of chemokine levels with types of reactions after alcohol consumption in patients with nonsteroidal anti-inflammatory drugs exacerbated respiratory disease (N-ERD)
D2.116 - Occupational asthma due to Chinese yeast, Yeast and Peptone
D2.117 - The interaction of exposure to air pollutants and inflammatory markers on lung function and asthma symptoms in asthmatic patients
D2.118 - Eosinophilic Esophagitis and Atopy: A Shared Mechanism of Type 2 Inflammation
D2.119 - Real-life experience in eosinophilic granulomatosis with polyangiitis (EGPA) after 12 months with mepolizumab 300mg in specialized autoimmune and asthma units in an Universitary Hospital
D2.122 - Dupilumab-Induced Diffuse Eosinophilic Drug Rash with Hypereosinophilia in a Patient with Idiopathic Pulmonary Fibrosis and Severe Asthma Exacerbation: A First Case Report
D2.123 - The impact of wartime environmental change on the frequency of asthma diagnoses
D2.124 - Clinical Characteristics and Predictors in Patients with Difficult-to-Treat Asthma
D2.125 - Occupational asthma in hairdressers due to hair dyes containing para-amino compounds
D2.127 - The bacterial lysate OM-85 mitigates HDM-induced allergic inflammation through the airway epithelial cell- macrophage crosstalk
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download